차입 증가 → 이자부담 → 수익성 악화
Critical부채가 +32.2% 늘며 이자보상배율이 -0.3x에서 -1.3x로 하락했다. ROE도 -2.7%에서 -16.8%로 낮아져 차입 부담이 수익성을 누르고 있다.
Evidence
부채 YoY +32.2%이자보상배율 -0.3x→-1.3xROE -2.7%→-16.8%
Chabiotech
A085660 · KOSDAQ₩8,110-1.34%
2026-08-25 closeChabiotech — pricey right now, or cheap? And what signals are flashing today?
The grade and valuation bands are below — free to read.
Loading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
New high + volume — the real recordrecord · not a prediction
Not this one stock, but every new-high-plus-volume pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-25)
Last 30 sessions
402 picks
Next-day win rate
51.6%
Avg next-day
-0.06%
vs market
-0.24%p
Beat the market on 45.3% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
08-23 60%08-21 36.4%08-20 44.4%08-19 0%08-18 27.3%08-14 23.1%08-13 41.7%08-12 70%08-11 77.8%08-10 22.2%08-07 61.5%08-06 27.3%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Trade plan
Decide the exit before you enter. Set what you are willing to lose first, and the share count follows — so you know the worst case before you buy.
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
This is a calculator, not advice, and it does not promise any outcome. You choose the stop and target — the button values (ATR, recent low/high) are observations from past prices. Actual fills depend on the order book and liquidity.
Valuation Grades
Relative to 292 건강관리 peers · not investment advice
C+
Overall: 건강관리 195/292 · top 67%
Factor composite · relative position in sector
Valuation in its own history
PER — · PBR 2.19 — own history (2005-12~) percentiles 30/100 · 81/100
PER30/100
PBR81/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -0.82
Distress
Grey
Safe
- Altman Z''
- -0.82
- Beneish M-Score
- -2.22
- Sloan accrual
- 1.89%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
1/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score1/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Margin trendWarning
영업외손익 급변 (영업이익 대비 85% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
KRAs of 2026-08-25건강관리
This stock is in 건강관리: revenue rank 13 of 287, share 1.7%.
13 / 2871.7%revenue share
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6차바이오텍1.7%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 14
- Median P/B
- 1.47
- Level
- 넓음
- n
- 263
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -4.6%
- Interest coverage
- -1.3x
- Return on equity (ROE)
- -2.8%
Operating margin −5pp
Operating lossInterest coverageBase -1.3x adverse case -2.7x
Return on equity (ROE)Base -2.8% adverse case -48.3%
Revenue −15%
Interest coverage riskInterest coverageBase -1.3x adverse case -1.1x
Return on equity (ROE)Base -2.8% adverse case -27.4%
Interest rate +2pp
Interest coverage riskInterest coverageBase -1.3x adverse case -0.6x
Return on equity (ROE)Base -2.8% adverse case -43.3%
Interest coverage limit
Already below the limit by 8.1ppInterest coverage limit at an operating margin of 3.6%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-06-09Suppliers disclosed by the company in its 2026-06-09 annual report.
Suppliers without disclosed amount
ProcessingBagOverwrapCordTransferFetalBovineSerumQualifiedAUSCRYOSERDMSO+34 more
Financials at a glance
Chabiotech's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 차광렬25.12%2026-07-03 · 증감 0.00%p
- 한화손해보험8.53%2026-02-06 · 증감 +8.53%p
Other stocks held by the same investors
A filing-based shared-holder record, not investment advice.
- 신한알파리츠KRA293940 →
Shared holders: 한화손해보험
Connections
AI-extracted related companies · for reference
Customers
서울아산병원서울대학교병원
Competitors
Same theme
미국식품의약국(FDA)에볼루션 바이오
📦 ETFs holding this stock
by weight · top-10 constituents basisPassive money holding this stock ≈ 4억(lower bound — top-10 basis, not a forecast)
Factual holdings info from daily disclosures — not a recommendation.
Look up another stock →Recent filings
Chabiotech's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy